nanotech investing Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
nanotech investing Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
nanotech investing ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
nanotech investing Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
nanotech investing Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
nanotech investing Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
